{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:57:18Z","timestamp":1792079838979,"version":"4.4.0"},"reference-count":22,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Beijing Association of Holistic Integrative Medicine","award":["ZHKY-2025-1407"],"award-info":[{"award-number":["ZHKY-2025-1407"]}]},{"name":"Open Project funded by Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education","award":["2025 Open Project-6"],"award-info":[{"award-number":["2025 Open Project-6"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Introduction: To investigate the diagnostic and prognostic value of commonly used immunohistochemical markers regarding high-grade disease, muscle-invasion bladder cancer (MIBC) and survival in bladder cancer. Methods: A total of 477 patients diagnosed with bladder cancer at Peking University Cancer Hospital between 2009 and 2024 were included. The immunohistochemical markers included CK7, CK20, GATA3, Uroplakin 3, CK5\/6, P40, P63, Syn, CD56, CGA, Vimentin, S100, LCA, Ki67, P53, Her2, EGFR, PD-L1, PD-1 tumor, PD-1 stroma, and Pan-TRK. Logistic analyses were used to determine the diagnostic value of the markers for high-grade disease and MIBC. Cox regression analyses were used to determine the prognostic value of the markers for survival. Results: We found Ki67 positivity (p &lt; 0.001) and Her2 positivity (p = 0.001) might have an association with high-grade disease, while no marker demonstrated diagnostic value for MIBC. Patients with CK7 positivity (p = 0.012), Uroplakin 3 positivity (p = 0.004), and PD-1 (stroma) positivity (p = 0.037) had better overall survival (OS) than those with negative expression, while Cox regression analyses showed only CK7 positivity (p = 0.025) and Uroplakin 3 positivity (p = 0.008) had prognostic value for better OS. However, considering there were only 2 CK7-negative patients, the sample size might be insufficient to demonstrate its prognostic value. Conclusions: These results suggest that Ki67 positivity and Her2 positivity might have association with high-grade disease, and Uroplakin 3 positivity might have prognostic value for better OS. However, these conclusions require further clarification through larger-scale studies in the future.<\/jats:p>","DOI":"10.3390\/jcm15156124","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T13:03:27Z","timestamp":1786021407000},"page":"6124","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Diagnostic and Prognostic Value of Immunohistochemical Markers in Bladder Cancer: A Real-World Study of 477 Patients"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2499-5706","authenticated-orcid":false,"given":"Xingxing","family":"Tang","sequence":"first","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Urology, Peking University Cancer Hospital & Institute, No. 52 Fucheng Road, Haidian District, Beijing 100142, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Liu","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Urology, Peking University Cancer Hospital & Institute, No. 52 Fucheng Road, Haidian District, Beijing 100142, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Zhao","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Urology, Peking University Cancer Hospital & Institute, No. 52 Fucheng Road, Haidian District, Beijing 100142, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Yang","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Urology, Peking University Cancer Hospital & Institute, No. 52 Fucheng Road, Haidian District, Beijing 100142, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Yang","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Urology, Peking University Cancer Hospital & Institute, No. 52 Fucheng Road, Haidian District, Beijing 100142, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Du","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Urology, Peking University Cancer Hospital & Institute, No. 52 Fucheng Road, Haidian District, Beijing 100142, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"key":"ref_1","first-page":"10","article-title":"Cancer Statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e076743","DOI":"10.1136\/bmj-2023-076743","article-title":"Advances in Diagnosis and Treatment of Bladder Cancer","volume":"384","author":"Cookson","year":"2024","journal-title":"BMJ"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/1078-0432.CCR-20-2488","article-title":"Open-Label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma","volume":"27","author":"Sheng","year":"2021","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Attanasio, G., Failla, M., Poidomani, S., Buzzanca, T., Salzano, S., Zizzo, M., Palicelli, A., Zanelli, M., Koufopoulos, N., and Russo, G.I. (2025). Histological and Immunohistochemical Approaches to Molecular Subtyping in Muscle-Invasive Bladder Cancer. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1546160"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"206","DOI":"10.4103\/jmau.jmau_45_21","article-title":"Immunohistochemical Analysis of P53, CD10 and Ki67 Expression as Prognostic Biomarkers in Urinary Bladder Carcinomas Correlating with Age, Histomorphology, Grade and Stage: An Institutional Study of One and Half Year","volume":"11","author":"Mohapatra","year":"2023","journal-title":"J. Microsc. Ultrastruct."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.eururo.2017.12.018","article-title":"Updates in the Eighth Edition of the Tumor-Node-Metastasis Staging Classification for Urologic Cancers","volume":"73","author":"Paner","year":"2018","journal-title":"Eur. Urol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.eururo.2022.07.002","article-title":"The 2022 World Health Organization Classification of Tumors of the Urinary System and Male Genital Organs-Part B: Prostate and Urinary Tract Tumors","volume":"82","author":"Netto","year":"2022","journal-title":"Eur. Urol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e617","DOI":"10.1093\/oncolo\/oyad070","article-title":"HER2 Expression Associated with Clinical Characteristics and Prognosis of Urothelial Carcinoma in a Chinese Population","volume":"28","author":"Zhou","year":"2023","journal-title":"Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"7369","DOI":"10.1158\/1078-0432.CCR-06-1472","article-title":"Ki-67 Is an Independent Predictor of Bladder Cancer Outcome in Patients Treated with Radical Cystectomy for Organ-Confined Disease","volume":"12","author":"Margulis","year":"2006","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1158\/1078-0432.CCR-06-2167","article-title":"Epidermal Growth Factor Receptor Protein Expression and Gene Amplification in Small Cell Carcinoma of the Urinary Bladder","volume":"13","author":"Wang","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Nasr, S., Haddad, F.G., Khazen, J., Kattan, J., and Trak-Smayra, V. (2023). PD-L1 Protein Expression by Combined Positive Score (CPS) in Patients with Muscle Invasive or Advanced Urothelial Carcinoma: A Single Institution Experience. BMC Cancer, 23.","DOI":"10.1186\/s12885-023-11299-y"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9","article-title":"The Ki-67 Protein: From the Known and the Unknown","volume":"182","author":"Scholzen","year":"2000","journal-title":"J. Cell. Physiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1038\/s41418-021-00823-x","article-title":"Ki-67 Gene Expression","volume":"28","author":"Uxa","year":"2021","journal-title":"Cell Death Differ."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Arman, K., Erg\u00fcn, S., Temiz, E., and Oztuzcu, S. (2014). The Interrelationship between HER2 and CASP3\/8 with Apoptosis in Different Cancer Cell Lines. Mol. Biol. Rep., 41.","DOI":"10.1007\/s11033-014-3700-x"},{"key":"ref_15","first-page":"121","article-title":"Assessment of the Expression Pattern of HER2 and Its Correlation with HER2-Targeting Antibody-Drug Conjugate Therapy in Urothelial Cancer","volume":"3","author":"Lei","year":"2023","journal-title":"J. Natl. Cancer Cent."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.7314\/APJCP.2015.16.4.1539","article-title":"High Expression Level of Preoperative Serum Uroplakin III Is Associated with Biologically Aggressive Bladder Cancer","volume":"16","author":"Tsumura","year":"2015","journal-title":"Asian Pac. J. Cancer Prev. APJCP"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Sikic, D., Keck, B., Wach, S., Taubert, H., Wullich, B., Goebell, P.J., Kahlmeyer, A., Olbert, P., Isfort, P., and Nimphius, W. (2017). Immunohistochemiocal Subtyping Using CK20 and CK5 Can Identify Urothelial Carcinomas of the Upper Urinary Tract with a Poor Prognosis. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0179602"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1083\/jcb.200204102","article-title":"Uroplakin IIIb, a Urothelial Differentiation Marker, Dimerizes with Uroplakin Ib as an Early Step of Urothelial Plaque Assembly","volume":"159","author":"Deng","year":"2002","journal-title":"J. Cell Biol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Kaushal, S., Khandakar, H., Kaushal, S., and Khandakar, H. (2021). Molecular Classification of Bladder Cancer. Modern Approach to Diagnosis and Treatment of Bladder Cancer, IntechOpen.","DOI":"10.5772\/intechopen.97393"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"101201","DOI":"10.1016\/j.isci.2020.101201","article-title":"Urothelial-to-Neural Plasticity Drives Progression to Small Cell Bladder Cancer","volume":"23","author":"Yang","year":"2020","journal-title":"iScience"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1309\/PYQC-17CB-063T-Q07J","article-title":"Uroplakin III Is a Highly Specific and Moderately Sensitive Immunohistochemical Marker for Primary and Metastatic Urothelial Carcinomas","volume":"113","author":"Kaufmann","year":"2000","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.urology.2007.11.128","article-title":"Loss Expression of Uroplakin III Is Associated with Clinicopathologic Features of Aggressive Bladder Cancer","volume":"72","author":"Matsumoto","year":"2008","journal-title":"Urology"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/15\/6124\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T13:12:07Z","timestamp":1786021927000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/15\/6124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":22,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["jcm15156124"],"URL":"https:\/\/doi.org\/10.3390\/jcm15156124","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,6]]}}}